Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 302 results
Tissue sample on a lab bench with digital pathology equipment in the background.

May 18, 2026

Revolutionizing Cancer Care: AstraZeneca and Roche's Pioneering AI Partnership

AstraZeneca and Roche Diagnostics are embarking on a transformative three-year partnership aimed at enhancing cancer care in Asia through advanced AI-driven digital pathology.This collaboration marks a significant milestone as it introduces AI-powered digital pathology across nine Asian markets, focusing on education and training to foster the adoption of these technologies. Given that Asia accounts for nearly half of global breast cancer cases and over 60% of new lung cancer diagnoses, the need
A minimalist representation of a biomarker test strip with a sample drop.

May 18, 2026

AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer

AstraZeneca and Roche Diagnostics Asia Pacific have initiated a three-year partnership aimed at enhancing digital pathology capabilities and cancer care in nine Asian markets. This collaboration seeks to promote the use of AI-driven digital and computational pathology, particularly focusing on improving biomarker testing for breast and lung cancers.With nearly half of breast cancer cases and over 60% of new lung cancer diagnoses occurring in Asia, precise biomarker testing is increasingly vital
A mammogram displayed on a lightbox with a breast tissue sample in a clinical setting.

May 16, 2026

iCAD Inc stock (US45071L1098): AI breast cancer imaging specialist in the spotlight after recent bus

iCAD Inc, a prominent player in AI-driven breast cancer imaging and therapy solutions, is currently in the spotlight following a series of recent product and business updates that could shape its future in the medtech landscape.The company has made strides with its ProFound AI mammography platform and advancements in its therapy segment, emphasizing a strategic focus on scalable, software-driven cancer care. Market observers are keenly analyzing how these developments might affect iCAD's competi
Flat illustration of a CT scanner with radiation waves

May 16, 2026

Siemens Healthineers Pushes AI Oncology on the World Stage, but a Plodding Diagnostics Unit Drags th

Siemens Healthineers is making strides in AI-driven oncology with the launch of a photon-counting CT scanner, yet its diagnostics division is dragging down overall performance, affecting stock value.At the recent European Society for Radiotherapy and Oncology congress, Siemens Healthineers introduced the NAEOTOM Alpha Prime RT Pro Edition, an advanced CT scanner aimed at enhancing radiation therapy precision while reducing patient radiation exposure. This innovation highlights the company's stra
A liquid biopsy sample in a test tube on a lab bench

May 15, 2026

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

The landscape of cancer detection is evolving rapidly, driven by advancements in artificial intelligence and liquid biopsy technologies, according to BCC Research's latest report.The global molecular diagnostics market, valued at $20.3 billion in 2024, is projected to grow significantly, reaching $42.6 billion by 2030. This growth, estimated at a compound annual growth rate (CAGR) of 13.1%, is fueled by technological innovations and increased investments in healthcare infrastructure. North Ameri
Minimalist illustration of a cancer cell and AI algorithm

May 15, 2026

Archimedis Digital Commits $2 Mn to Expand AI-Led Life Sciences Innovation

Archimedis Digital has announced a significant investment of $2 million aimed at enhancing its AI-driven initiatives within the life sciences sector, particularly in cancer diagnosis and scientific data management.This funding will facilitate the creation of AI-first solutions, specifically targeting applications in histopathology and oncology diagnostics. The investment comes as the demand for intelligent systems that boost speed, accuracy, and predictive capabilities in healthcare grows. Archi
A minimalist heart silhouette with circuit patterns, representing AI in cardiac diagnostics.

May 14, 2026

A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

VentriPoint Diagnostics Ltd., a Toronto-based AI cardiac diagnostics firm, has achieved significant milestones, underscoring its potential in the medtech landscape. The company’s VMS+™ 4.0 system recently garnered a prestigious Edison Award and is advancing towards regulatory approval in China, marking a critical step in its growth trajectory.The AI-driven cardiac diagnostics market is rapidly evolving, projected to reach approximately $2.78 billion by 2026 and surpass $14 billion by 2034. This
Medical imaging system interface in a hospital IT office

May 14, 2026

Synektik S.A. stock (PLSYNEK00016): IT solutions provider for healthcare

Synektik S.A., a Polish IT firm specializing in healthcare solutions, is making strides in the European market for hospital software and imaging systems, attracting attention from U.S. investors amid the growing demand for digital health technologies.In its latest financial report, Synektik S.A. highlighted ongoing advancements in its medical imaging and hospital management software sectors. The company, listed on the Warsaw Stock Exchange, focuses on providing IT solutions tailored for healthca
A histopathology slide under a microscope in a clinical lab setting.

May 12, 2026

Artera gets FDA clearance for AI breast cancer risk prediction tool

Artera has achieved FDA clearance for its AI-driven tool designed to predict the risk of distant metastases in specific breast cancer cases.This new technology, known as ArteraAI Breast, leverages histopathology images alongside clinical variables to categorize patients into low- and high-risk groups for developing advanced breast cancer. The FDA's clearance focuses on patients with early-stage, hormone receptor-positive, HER2-negative invasive breast cancer, a demographic that typically undergo
A flat illustration of a radiology film with an AI brain overlay in a dark color scheme.

May 12, 2026

Ainovis, the healthtech company revolutionizing medical imaging diagnostics through generative AI, closes a €680,000 investment round

Ainovis, a Spanish healthtech startup, has secured €680,000 in a recent funding round aimed at enhancing medical imaging diagnostics through generative AI technology.Founded by Pablo Menéndez, Manuel Cerezo, and Miguel Herencia, Ainovis is focused on alleviating the pressures faced by radiology departments due to increasing demands for imaging studies. Backed by Kunsen Ventures and prominent figures in the medical field, the company aims to integrate AI solutions to support healthcare profession
A patient on an MRI machine in a clinical setting

May 12, 2026

Why the United States Medical Imaging Market Is Growing With AI and Advanced Diagnostics

The U.S. medical imaging market is witnessing significant growth, largely driven by advancements in technology and the increasing prevalence of chronic diseases.The market, valued at $10.7 billion in 2025, is projected to reach $13.8 billion by 2034, reflecting a compound annual growth rate (CAGR) of 2.78%. This growth is largely attributed to the rising incidence of chronic conditions such as cardiovascular diseases and cancer, which necessitate ongoing monitoring and precise diagnostics. Medic
A tissue sample on a microscope slide in a dimly lit lab

May 11, 2026

Roche and PathAI strike AI diagnostics deal worth up to $1B

Roche has announced a significant $1 billion agreement to acquire PathAI, a leader in AI-driven digital pathology, as part of its strategy to enhance cancer diagnostics. The deal includes an upfront payment of $750 million, with an additional $300 million contingent on future milestones.This acquisition is a strategic move for Roche, aimed at expanding its digital pathology and precision medicine initiatives. It builds on a partnership established in 2021, which focused on developing AI-enabled